Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since. Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver mutations,” in contrast to those merely along for the ride as “passenger mutations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific genetic vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allows us to construct drugs with best-in-class properties from the ground up.

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences Development Co. LLC, part of EXACT Sciences Corp., is an American company. The firm engages in research and development diagnostic test for cancer.

Qingdao Weilan Biological Group Co., Ltd., established on 2007-08-22, Business scope includes licensed projects:Import and export;Technology Import and Export;food business(Selling prepackaged food);Catering Services;Food Internet Sales;Food Internet Sales(Selling prepackaged food);food business;Health food sales;Sales of formula food for special medical purposes;Veterinary drug business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Research and development of bio-based materials technology;R&D of industrial enzyme preparations;Biomass liquid fuel production process research and development;Bio-feed R&D;Bio-organic fertilizer research and development;Fermentation process optimization technology research and development;Biochemical product technology research and development;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Food Additive Sales;Engage in investment activities with own funds;Animal Husbandry and Fishery Feed Sales;Feed Raw Material Sales;Feed Additive Sales;business management;property management;Conference and Exhibition Services;internet sales(Except for products that require a license for sale);Cosmetics Wholesale;Cosmetics Retail;Sales of hygiene products and single-use medical products;Personal Hygiene Sales;Daily necessities sales;Daily necessities wholesale;Daily miscellaneous goods sales;Pet Food and Supplies Wholesale;Pet food and supplies retail;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Health Consulting Services(Does not include medical services);Development of Human Gene Diagnosis and Therapy Technology;Chemical product sales(No licensed chemical products);Sales of Class I Medical Devices;Disinfectant sales(Free of Hazardous Chemicals);Business Management Consulting;Educational Consulting Services(Education and training activities that do not include licensing approval).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of MOH Holdings Pte Ltd., Singapore Health Services Pte Ltd. is a Singaporean company located in Singapore. The firm provides medical services. Ivy Ng is the CEO, in this role since 2012.

Suzhou Kebei Biotechnology Co., Ltd., established on 2009-09-10, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;R&D and application of cell technology;Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Yaneng Biotechnology produces a gene diagnostic chip technology platform. They provide cervical cancer screening and hereditary disease diagnostics, such as pre pregnancy and prenatal diagnosis and screening tests, and automatic nucleic acid extractor.  They also provide resarch and development services.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Thrombogenics, Inc., a subsidiary of Oxurion NV, is a company headquartered in New York, NY. The firm operates as a biotechnology company engages in delivering innovative treatments for diseases of the back of the eye with a focus on diabetic eye disease.

Tianjin Paige Biotechnology Co., Ltd., established on 2003-09-24, Business scope includes biological products,Health products,Fine Chemicals,Research and development of public health and environmental protection equipment,Technical Advisory Services,technology transfer;Self-operated and agency goods import and export,Technology Import and Export(National law,Except for items prohibited by laws and regulations).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Shanghai Hanuowei Biotechnology Co., Ltd., established on 2019-10-16, The scope of business includes engaging in biotechnology,Chemical Technology,Medical Technology,Technology development in the field of medical technology,Technical Services,technical consulting,technology transfer,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),laboratory equipment,Class I medical device,Class II medical device,chemical reagent(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)Wholesale,retail,Three types of medical device business(See license for specific items),Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.]

Heilongjiang Yipin Biotechnology Co., Ltd., established on 2017-05-05, Business scope includes biotechnology extension services,Production,Sales:Lysine,threonine,Tryptophan,Alanine,ammonium sulfate,Pentylenediamine and its products,single feed,compound feed,mixed feed,Corn starch and by-products,grain germ,organic fertilizer,soil conditioner,Grain Purchase,Processing and sales,Sale of fly ash,Railway Freight Transport Services,Import and export business.

Guangzhou Saiye Baimu Biotechnology Co., Ltd., established on 2020-03-10, Business scope includes technical services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Laboratory animal cage sales;Medical Research and Experimental Development;Natural science research and experimental development;Experimental animal production;Experimental animal management;Technology Import and Export;Import and export

Shanghai Shendao Biotechnology Co., Ltd., established on 2017-10-13, The scope of business includes engaging in biotechnology,Chemical Technology,Medical Technology,Technology development in the field of medical device technology,Technical Services,technology transfer,technical consulting,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),laboratory equipment,Sales of Medical Devices,Engaged in the import and export of goods and technologies. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Syngenta AG is a global company that produces agrochemicals and seeds and is based in Basel, Switzerland. As a biotechnology company, it conducts genomic research. It was formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. As of 2014 Syngenta is the world’s largest crop chemical producer As of 2009 it ranked third in seeds and biotechnology sales. Sales in 2015 were approximately US$13.4 billion, over half of which were in emerging markets. It is owned by ChemChina, a Chinese state-owned enterprise.

OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services.